Immix Biopharma, Inc. Common Stock (IMMX) Stock Price
IMMXStock
$7.98+195.56%52W
Market Cap$661.57M
P/E—
PEG Ratio—
Div yield—
Beta0.24
IMMX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-28.89%
Price vs S&P 500 (4W)-34.68%
VGM Score60.01
IMMX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.18 | -$0.18 | -2.44%(-$0.00) | |
| Q1 2026 | -$0.21 | -$0.18 | +13.25%(+$0.03) | |
| Q4 2025 | -$0.16 | -$0.28 | -75.00%(-$0.12) | |
| Q3 2025 | -$0.19 | -$0.24 | -26.32%(-$0.05) | |
| Q2 2025 | -$0.16 | -$0.22 | -37.50%(-$0.06) |
IMMX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.10
4.17
4.15
4.15
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
IMMXImmix Biopharma, Inc. Common Stock | — | — | B | — | — | — | — | $7.98 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Immix Biopharma, Inc. Common Stock
Immix Biopharma is a clinical-stage biopharmaceutical company developing novel cell therapies for oncology and inflammatory diseases using its proprietary TME Normalization Technology. This platform enables therapeutics to penetrate tumors and simultaneously target multiple components of the tumor microenvironment. The company's pipeline includes CAR-T candidate NXC-201 for autoimmune diseases and IMX-110 for soft tissue sarcoma.